FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213980463> ?p ?o ?g. }

• W3213980463 endingPage "132.e14" @default.
• W3213980463 startingPage "132.e1" @default.
• W3213980463 abstract "Background 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use of 17α-hydroxyprogesterone caproate for the prevention of preterm birth in pregnant women, little is known about the long-term effects of 17α-hydroxyprogesterone caproate on the health of the offsprings. Objective To examine the association between in utero exposure to 17α-hydroxyprogesterone caproate and the risk of cancer in the offspring. Study Design The Child Health and Development Studies was a population-based cohort of >18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, CA) between 1959 and 1966. Clinical information was abstracted from the mothers’ medical records beginning 6 months before pregnancy through delivery. We identified the number and timing of 17α-hydroxyprogesterone caproate injections during pregnancy. Incident cancers diagnosed in the offspring were ascertained through 2019 by linkage to the California Cancer Registry. We used the Cox proportional hazard models to estimate the adjusted hazard ratios and their 95% confidence intervals, with the follow-up time accrued from the date of birth through the date of cancer diagnosis, death, or last contact. Results A total of 1008 offspring were diagnosed with cancer over 730,817 person-years of follow-up. Approximately 1.0% of the offspring (n=234) were exposed in utero to 17α-hydroxyprogesterone caproate. Exposure in the first trimester was associated with an increased risk of any cancer (adjusted hazard ratio, 2.57; 95% confidence interval, 1.59–4.15), and the risk increased with the number of injections (1–2 injections: adjusted hazard ratio, 1.80; 95% confidence interval, 1.12–2.90; ≥3 injections: adjusted hazard ratio, 3.07; 95% confidence interval, 1.34–7.05). Exposure in the second or third trimester conferred an additional risk for the male (adjusted hazard ratio, 2.59; 95% confidence interval, 1.07–6.28) but not for the female (adjusted hazard ratio, 0.30; 95% confidence interval, 0.04–1.11) offspring. The risk of colorectal (adjusted hazard ratio, 5.51; 95% confidence interval, 1.73–17.59), prostate (adjusted hazard ratio, 5.10; 95% confidence interval, 1.24–21.00), and pediatric brain (adjusted hazard ratio, 34.72; 95% confidence interval, 7.29–164.33) cancer was higher in the offspring first exposed to 17α-hydroxyprogesterone caproate in the first trimester than the offspring not exposed. Conclusion Caution using 17α-hydroxyprogesterone caproate in early pregnancy is warranted, given the possible link with cancer in the offspring. 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use of 17α-hydroxyprogesterone caproate for the prevention of preterm birth in pregnant women, little is known about the long-term effects of 17α-hydroxyprogesterone caproate on the health of the offsprings. To examine the association between in utero exposure to 17α-hydroxyprogesterone caproate and the risk of cancer in the offspring. The Child Health and Development Studies was a population-based cohort of >18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, CA) between 1959 and 1966. Clinical information was abstracted from the mothers’ medical records beginning 6 months before pregnancy through delivery. We identified the number and timing of 17α-hydroxyprogesterone caproate injections during pregnancy. Incident cancers diagnosed in the offspring were ascertained through 2019 by linkage to the California Cancer Registry. We used the Cox proportional hazard models to estimate the adjusted hazard ratios and their 95% confidence intervals, with the follow-up time accrued from the date of birth through the date of cancer diagnosis, death, or last contact. A total of 1008 offspring were diagnosed with cancer over 730,817 person-years of follow-up. Approximately 1.0% of the offspring (n=234) were exposed in utero to 17α-hydroxyprogesterone caproate. Exposure in the first trimester was associated with an increased risk of any cancer (adjusted hazard ratio, 2.57; 95% confidence interval, 1.59–4.15), and the risk increased with the number of injections (1–2 injections: adjusted hazard ratio, 1.80; 95% confidence interval, 1.12–2.90; ≥3 injections: adjusted hazard ratio, 3.07; 95% confidence interval, 1.34–7.05). Exposure in the second or third trimester conferred an additional risk for the male (adjusted hazard ratio, 2.59; 95% confidence interval, 1.07–6.28) but not for the female (adjusted hazard ratio, 0.30; 95% confidence interval, 0.04–1.11) offspring. The risk of colorectal (adjusted hazard ratio, 5.51; 95% confidence interval, 1.73–17.59), prostate (adjusted hazard ratio, 5.10; 95% confidence interval, 1.24–21.00), and pediatric brain (adjusted hazard ratio, 34.72; 95% confidence interval, 7.29–164.33) cancer was higher in the offspring first exposed to 17α-hydroxyprogesterone caproate in the first trimester than the offspring not exposed. Caution using 17α-hydroxyprogesterone caproate in early pregnancy is warranted, given the possible link with cancer in the offspring." @default.
• W3213980463 created "2021-11-22" @default.
• W3213980463 creator A5030804423 @default.
• W3213980463 creator A5062111882 @default.
• W3213980463 creator A5078854117 @default.
• W3213980463 creator A5084328367 @default.
• W3213980463 date "2022-01-01" @default.
• W3213980463 modified "2023-10-14" @default.
• W3213980463 title "In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring" @default.
• W3213980463 cites W103436252 @default.
• W3213980463 cites W1511256976 @default.
• W3213980463 cites W1529768174 @default.
• W3213980463 cites W1589646695 @default.
• W3213980463 cites W1612896483 @default.
• W3213980463 cites W1845661996 @default.
• W3213980463 cites W1907735402 @default.
• W3213980463 cites W1909375041 @default.
• W3213980463 cites W1967011752 @default.
• W3213980463 cites W1967936354 @default.
• W3213980463 cites W1968640856 @default.
• W3213980463 cites W1975621320 @default.
• W3213980463 cites W1980524281 @default.
• W3213980463 cites W1982611692 @default.
• W3213980463 cites W1984890236 @default.
• W3213980463 cites W1990474798 @default.
• W3213980463 cites W1990485596 @default.
• W3213980463 cites W1996083321 @default.
• W3213980463 cites W1997013992 @default.
• W3213980463 cites W2004172374 @default.
• W3213980463 cites W2011920442 @default.
• W3213980463 cites W2013587349 @default.
• W3213980463 cites W2015288212 @default.
• W3213980463 cites W2027109773 @default.
• W3213980463 cites W2030555662 @default.
• W3213980463 cites W2039100882 @default.
• W3213980463 cites W2044208752 @default.
• W3213980463 cites W2046262003 @default.
• W3213980463 cites W2050520657 @default.
• W3213980463 cites W2053392834 @default.
• W3213980463 cites W2055316985 @default.
• W3213980463 cites W2057224309 @default.
• W3213980463 cites W2062004184 @default.
• W3213980463 cites W2065614074 @default.
• W3213980463 cites W2073174983 @default.
• W3213980463 cites W2073889567 @default.
• W3213980463 cites W2075605442 @default.
• W3213980463 cites W2081278205 @default.
• W3213980463 cites W2094225101 @default.
• W3213980463 cites W2132240938 @default.
• W3213980463 cites W2136264604 @default.
• W3213980463 cites W2136988329 @default.
• W3213980463 cites W2138182947 @default.
• W3213980463 cites W2143721196 @default.
• W3213980463 cites W2143770094 @default.
• W3213980463 cites W2145926321 @default.
• W3213980463 cites W2146655274 @default.
• W3213980463 cites W2148043422 @default.
• W3213980463 cites W2148619299 @default.
• W3213980463 cites W2150272037 @default.
• W3213980463 cites W2156478475 @default.
• W3213980463 cites W2192373951 @default.
• W3213980463 cites W2257991194 @default.
• W3213980463 cites W2327100938 @default.
• W3213980463 cites W2408997078 @default.
• W3213980463 cites W2439602674 @default.
• W3213980463 cites W2511902538 @default.
• W3213980463 cites W2768036168 @default.
• W3213980463 cites W2889074770 @default.
• W3213980463 cites W2889609693 @default.
• W3213980463 cites W2902914441 @default.
• W3213980463 cites W2912618139 @default.
• W3213980463 cites W2970130346 @default.
• W3213980463 cites W2981584661 @default.
• W3213980463 cites W2985810567 @default.
• W3213980463 cites W3002354567 @default.
• W3213980463 cites W3015927522 @default.
• W3213980463 cites W3037195516 @default.
• W3213980463 cites W3091881527 @default.
• W3213980463 cites W3095642234 @default.
• W3213980463 cites W3096965219 @default.
• W3213980463 cites W3097694467 @default.
• W3213980463 cites W3097918626 @default.
• W3213980463 cites W3138680213 @default.
• W3213980463 cites W3159122618 @default.
• W3213980463 cites W3179533456 @default.
• W3213980463 cites W4248800138 @default.
• W3213980463 cites W4290437308 @default.
• W3213980463 cites W4298048951 @default.
• W3213980463 cites W4300603122 @default.
• W3213980463 cites W4375846322 @default.
• W3213980463 cites W51079071 @default.
• W3213980463 doi "https://doi.org/10.1016/j.ajog.2021.10.035" @default.
• W3213980463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34767803" @default.
• W3213980463 hasPublicationYear "2022" @default.
• W3213980463 type Work @default.
• W3213980463 sameAs 3213980463 @default.
• W3213980463 citedByCount "13" @default.
• W3213980463 countsByYear W32139804632022 @default.

• next